tradingkey.logo

Elutia Inc

ELUT
查看詳細走勢圖
0.586USD
+0.044+8.03%
收盤 12/19, 16:00美東報價延遲15分鐘
24.95M總市值
虧損本益比TTM

Elutia Inc

0.586
+0.044+8.03%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+8.03%

5天

-15.99%

1月

-4.67%

6月

-67.61%

今年開始到現在

-84.32%

1年

-87.89%

查看詳細走勢圖

TradingKey Elutia Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Elutia Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在藥品行業排名89/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價3.50。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Elutia Inc評分

相關信息

行業排名
89 / 158
全市場排名
222 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
3.500
目標均價
+416.22%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Elutia Inc亮點

亮點風險
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
業績增長期
公司處於發展階段,最新年度總收入24.38M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入24.38M美元
估值高估
公司最新PE估值-0.94,處於3年歷史高位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉61.99K股

Elutia Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Elutia Inc簡介

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
公司代碼ELUT
公司Elutia Inc
CEOMills (C. Randal)
網址https://elutia.com/

常見問題

Elutia Inc(ELUT)的當前股價是多少?

Elutia Inc(ELUT)的當前股價是 0.586。

Elutia Inc 的股票代碼是什麼?

Elutia Inc的股票代碼是ELUT。

Elutia Inc股票的52週最高點是多少?

Elutia Inc股票的52週最高點是4.840。

Elutia Inc股票的52週最低點是多少?

Elutia Inc股票的52週最低點是0.500。

Elutia Inc的市值是多少?

Elutia Inc的市值是24.95M。

Elutia Inc的淨利潤是多少?

Elutia Inc的淨利潤為-53.95M。

現在Elutia Inc(ELUT)的股票是買入、持有還是賣出?

根據分析師評級,Elutia Inc(ELUT)的總體評級為買入,目標價格為3.500。

Elutia Inc(ELUT)股票的每股收益(EPS TTM)是多少

Elutia Inc(ELUT)股票的每股收益(EPS TTM)是-0.626。
KeyAI